Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab
作者: Onder TonyaliUgur CoskunSinemis YukselMevlude InancOznur BalTulay AkmanDogan YazilitasArife UlasMehmet KucukonerAsude AksoyUmut DemirciMukremin UysalOzgur TanriverdiYusuf GunaydinAhmet Taner SumbulRamazan YildizHalit KaracaBerna OksuzogluAydin CiltasSuleyman BuyukberberMustafa Benekli
作者单位: 1Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Mustafa Kemal University, Hatay, Turkey
2Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey
3Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey
4Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Turkey
5Department of Medical Oncology, Ankara Oncology Training and Research Hospital, Ankara, Turkey
6Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
7Department of Medical Oncology, Konya Numune Education and Research Hospital, Konya, Turkey
8Department of Medical Oncology, Ali Osman Sonmez Oncology Hospital, Bursa, Turkey
9Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
10Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Inonu University, Malatya, Turkey
11Department of Medical Oncology, Ankara Ataturk Education and Research Hospital, Ankara, Turkey
12Division of Medical Oncology, Department of Internal Medicine, Afyon Kocatepe University Faculty of Medicine, Afyonkarahisar, Turkey
13Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Mugla University, Mugla, Turkey
刊名: The Breast, 2016, Vol.25 , pp.22-26
来源数据库: Elsevier Journal
DOI: 10.1016/j.breast.2015.11.006
关键词: Breast cancerAdjuvant therapyTrastuzumabBrain metastasis
英文摘要: Abstract(#br)Purpose(#br)The aim of this study was to determine risk factors for brain metastasis as the first site of disease recurrence in patients with HER2-positive early-stage breast cancer (EBC) who received adjuvant trastuzumab.(#br)Methods(#br)Medical records of 588 female patients who received 52-week adjuvant trastuzumab from 14 centers were evaluated. Cumulative incidence functions for brain metastasis as the first site of disease recurrence and the effect of covariates on brain metastasis were evaluated in a competing risk analysis and competing risks regression, respectively.(#br)Results(#br)Median follow-up time was 36 months. Cumulative incidence of brain metastasis at 12 months and 24 months was 0.6% and 2%, respectively. HER2-enriched subtype (ER− and PR−) tumor ( p =...
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:2.491 (2011)

×